Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Promethazine/sumatriptan - Charleston Laboratories

Drug Profile

Promethazine/sumatriptan - Charleston Laboratories

Alternative Names: CL-H1T; sumatriptan succinate/promethazine HCl - Charleston Laboratories

Latest Information Update: 21 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Charleston Laboratories
  • Class Amines; Antiemetics; Antimigraines; Indoles; Phenothiazines; Small molecules; Sulfonamides
  • Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Migraine; Nausea and vomiting

Most Recent Events

  • 21 Mar 2023 Promethazine/sumatriptan (CL H1T) is still in phase III trials for Migraine in USA (PO)
  • 21 Mar 2023 Promethazine/sumatriptan (CL H1T) is still in phase III trials for Nausea and vomiting (Prevention) in USA (PO)
  • 23 Feb 2021 Phase-III clinical trials in Migraine in USA (PO) (Charleston Laboratories pipeline, February 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top